Glossary
|
Site Map
|
Contact Us
about us
product pipeline
technology
clinical trials
investors & news
careers
•
Management
•
Board of Directors
•
Collaborations
•
Brentuximab Vedotin
(SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
•
ASG-5ME
•
Preclinical Programs
•
Scientific Publications
•
ADC Technology
•
SEA Technology
•
Scientific Publications
By Program:
•
Brentuximab Vedotin
(SGN-35)
•
Lintuzumab (SGN-33)
•
Dacetuzumab (SGN-40)
•
SGN-70
•
SGN-75
•
ASG-5ME
By Indication:
•
Hodgkin Lymphoma
•
Non-Hodgkin Lymphoma
•
Multiple Myeloma
•
Leukemia/MDS
•
Autoimmune
•
Solid Tumors
•
Press Releases
•
Stock Performance
•
SEC Filings
•
Webcasts & Events
•
Scientific Publications
•
Corporate Governance
•
Analyst Coverage
•
Financial Reports
•
Investor FAQ
•
Information Request
•
Benefits
•
Living in the Area
•
Job Opportunities
You need to upgrade your Flash Player to version 9 or newer.
In the News
09/02/2010
Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas
08/04/2010
Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference
Webcasts and Events
Event:
Second Quarter 2010 Financial Results Conference Call
Date:
07/27/2010
Time:
02:00 PM ET
Event:
Canaccord Genuity 30th Annual Growth Conference
Date:
08/10/2010
Time:
09:30 AM ET